Role of nuclear factor-κB in breast and colorectal cancer

Current Allergy and Asthma Reports

Volumn 13, Issue 1, 2013, Pages 44-49

  Zubair, Adeel ^a   Frieri, Marianne ^b  

^a Nassau University Medical Center ^*  (United States)

^b NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Cancer; Carcinoma; Colorectal cancer; I kappa B; Neoplasm; NF kappa B; NF B; Nuclear factor B

Indexed keywords

3 (4 CHLOROPHENYL)ADAMANTANE 1 CARBOXYLIC ACID(PYRISIN 4 YLMETHYL)AMIDE; ABC 294640; BORTEZOMIB; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARTHENOLIDE; TAMOXIFEN; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESEARCH; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL SURVIVAL; COLON CARCINOGENESIS; COLORECTAL CANCER; CYTOKINE PRODUCTION; DNA POLYMORPHISM; DRUG RESEARCH; GENE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; INFLAMMATORY BREAST CANCER; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; NK KAPPAB GENE; NONHUMAN; PROTEIN FUNCTION; REL GENE;

EID: 84872607526     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-012-0300-5     Document Type: Article

References (71)

1. Pazin MJ, Sheridan PL, Cannon K, et al. NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev. 1996;10:37-49.
2. Silverman N, Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001;15:2321-42. (Pubitemid 32899738)
3. Ghosh S, May MJ, Kopp EB. NF-kB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-60. (Pubitemid 28183365)
4. Shishodia S, Amin HM, Lai R, et al. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005;70:700-13. (Pubitemid 41058705)
5. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001;7:401-9. (Pubitemid 32206507)
6. Hayden MS, Ghosh S. Signaling to NF-kB. Genes Dev. 2004;18:2195-224. (Pubitemid 39209568)
7. Hayden MS, Ghosh S. Shared principles in NF-kB signaling. Cell. 2008;132:344-62. (Pubitemid 351192002)
8. •• Hayden MS, Ghosh S. NF-kB in immunobiology. Cell Res. 2011;21:223-44. This excellent review focused on innate and adaptive immune responses, development and maintenance of cells and tissues, areas of recent progress while also providing a broad overview of the roles of NF-κB in mammalian immunobiology.
9. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26:203-34.
10. • Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem. 2010;336:25-37. The mechanism that leads to constitutive activation of NF-kappaB in hematological, gastrointestinal, genitourinary, gynecological, thoracic head and neck, breast, and skin cancers, and the ways NF-kappaB is activated are the topics of discussion in this review.
11. Giri DK, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem. 1998;273:14008-14. (Pubitemid 28268457)
12. Ghosh S, Baltimore D. Activation in vitro of NF-kB by phosphorylation of its inhibitor IkB. Nature. 1990;344:678-82. (Pubitemid 20108372)
13. Beg AA, Baldwin Jr AS. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev. 1993;11:2064-70.
14. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene. 2006;25:6706-16. (Pubitemid 44657847)
15. Mansur A, Karnik A, Frieri M. Nitric oxide production and apoptosis by gp 120. Allergy and Asthma Proc. 2000;21:145-9.
16. Dzhindzhikhashvili M, Jaghab MA, Frieri M. Lymphadenopathy, productive cough, eosinophila and a new onset acquired immundeficiency syndrome. Allergy Asthma Proc. 2011;32:1-6.
17. Mansur A, Therattil J, Frieri M. An atypical case of hypogammaglobulinemia. Ann Allergy Asthma Immunol. 2000;84:583-6. (Pubitemid 30418857)
18. Frisella PD, Joks R, Frieri M. Transforming growth factor-beta. A Role in the upper airway and rhinosinusitis: D. Pteronyssinusi induced apoptosis with pulmonary alveolar cells. Am J. Rhinology. 2011;25:231-5.
19. Frieri M. Accelerated atherosclerosis in systemic lupus erythematosus. Role of proinflammatory cytokines and therapeutic approaches. Current Allergy & Asthma Report. 2011;12(1):25-32.
20. Frieri M, Samih M, Liu H, et al. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol. 2012.
21. Frieri M. Chemotherapy Effects in an Infant with Familial Hemophagocytic Lymphohistiocytosis. Int-J World Allergy Org. 2006; 18/6.
22. •• Hurtado-Cordovi JM, Avezbakiyev B, Frieri M et al. Inflammatory Malignant Fibrous Histiocytoma Presenting with a Leukemoid Reaction: A Case Report and Review of the Literature. Case Reports in Medicine. Volume 2012. ISRN Oncology, 2012. Following review of medical literature, this appears to be the first reported case of inflammatory cutaneous MFH associated with a leukemoid reaction. This histological variant is rare, and carries a poor prognosis. Therefore there is a need for investigating alternative therapies capable of improving the survival of these patients.
23. Hinohara K, Gotosh N. Inflammatory signaling pathways in self-renewing breast cancer stem cells. Curr Opin Pharmacol. 2010;10:650-4.
24. Baker RG, Hayden MS, Ghosh S. NF-kB, inflammation, and metabolic disease. Cell Metab. 2011;12:11-22.
25. Aranha MM, Borralho PM, Ravasco P, et al. NF-κB and apoptosis in colorectal tumourigenesis. Eur J Clin Invest. 2007;37:416-24. (Pubitemid 46653143)
26. Angileri FF, Aguennouz M, Conti A, et al. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer. 2008;112:2258-66. (Pubitemid 351628637)
27. Anto RJ, Mukhopadhyay A, Denning K, et al. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis. 2002;23:143-50. (Pubitemid 34213563)
28. Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNF-alfa-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalfa kinase and TGF-beta-activated kinase-1. J Immunol. 2007;178:2507-16. (Pubitemid 46233452)
29. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkB activation. J Biol Chem. 1997;272:2042-5. (Pubitemid 27058475)
30. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell. 2002;109:S81-96. (Pubitemid 34457854)
31. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-63. (Pubitemid 30365393)
32. Karin M, Greten FR. NF-KappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-59. (Pubitemid 41400849)
33. Kumar A, Takada Y, Boriek AM, et al. Nuclear factor-kappaB: its role in health and disease. J Mol Med. 2004;82:434-48. (Pubitemid 39044283)
34. Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol. 1999;19:350-64. (Pubitemid 30039103)
35. Sethi G, Ahn KS, Sandur SK, et al. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem. 2006;281:23425-35. (Pubitemid 44274117)
36. van der Saag PT, Caldenhoven E, van de Stolpe A. Molecular mechanisms of steroid action: a novel type of crosstalk between glucocorticoids and NF-kappa B transcription factors. Eur Respir J Suppl. 1996;22:146s-53s.
37. Noguchi Y, Makino T, Yoshikawa T, et al. The possible role of TNF-alpha and IL-2 in inducing tumor-associated metabolic alterations. Surg Today. 1996;26:36-41. (Pubitemid 26064357)
38. Marrogi A, Pass HI, Khan M, et al. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res. 2000;60:3696-700. (Pubitemid 32204553)
39. Kalgutkar AS, Zhao Z. Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. Curr Drug Targets. 2001;2:79-106. (Pubitemid 32409746)
40. Ghosh CC, Ramaswami S, Juvekar A, et al. Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα. J Immunol. 2010;185:3685-93.
41. Antoon JW, White MD, Slaughter EM, et al. Targeting NFκB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol and Ther. 2011;7:678-89.
42. Bertucci F, Finetti P, Rougemont J, et al. Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. Cancer Res. 2006;64:8558-65.
43. deGraffenried LA, Chandrasekar B, Friedrichs WE, et al. NF-Kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol. 2004;15:885-90. (Pubitemid 39004343)
44. Biswas DK, Singh S, Shi Q, et al. Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE. 2005;288:27.
45. Evans MJ, Eckert A, Lai K, et al. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ Res. 2001;89:823-30. (Pubitemid 34633854)
46. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992;10:1014-24.
47. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692-6.
48. Frasor J, Weaver A, Pradhan M, et al. Positive Crosstalk between Estrogen Receptor and NFκB in Breast Cancer. Cancer Res. 2010;69:8918-25.
49. Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab. 2005;16:46-52. (Pubitemid 40270849)
50. Hinohara K, Kobayashi S, Kanauchi H, et al. ErbB receptor tyrosine kinase/NF-{kappa}B signaling controls mammosphere formation in human breast cancer. PNAS. 2012;109(17):6584-9.
51. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584-9. (Pubitemid 26300127)
52. Lerebours F, Vacher S, Andrieu C, et al. NF-kappa B genes have a major role in Inflammatory Breast Cancer. BMC Cancer. 2008;8:41. (Pubitemid 351420101)
53. Pan Q, Bao LW, Kleer CG, et al. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther. 2003;2:617-22.
54. Riggins RB, Zwart A, Nehra R, et al. The nuclear Factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 2005;4:33-41. (Pubitemid 40268064)
55. •• Santini D, Perrone G, Roato I, et al. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol. 2011;226:780-4. Receptor activator of NFκB ligand (RANKL), represents the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases. These data highlight the central role of RANK/RANKL/OPG pathway as potential therapeutic target not only in bone metastasis management, but also in the adjuvant setting.
56. Santini D, Schiavon G, Vincenzi B, et al. Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. PLoS ONE. 2011;6(4)
57. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 2007;22:1387-98. (Pubitemid 47470331)
58. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6:3282-9. (Pubitemid 30637758)
59. Van Laere S, Van der Auwera I, Van den Eynden GG, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat. 2005;93:237-46. (Pubitemid 41441293)
60. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res. 2006;12:3249-56.
61. Whelan J, Ghersa P, van Huijsduijnen RH, et al. An NF kappa B-like factor is essential but not sufficient for cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Nucleic Acids Res. 1991;19:2645-53. (Pubitemid 21896900)
62. Zhou Y, Eppenberger-Castori S, Eppenberger U, et al. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer. 2005;12:37-46. (Pubitemid 41398155)
63. Zhou Y, Eppenberger-Castori S, Marx C, et al. Activation of nuclear factor-kappab (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol. 2004;37:1130-44. (Pubitemid 40311751)
64. Zhou Y, Yau C, Gray JW, et al. Enhanced NFKB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer. 2007;7:59. (Pubitemid 46614509)
65. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, et al. PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol. 2006;132:76-84. (Pubitemid 41752048)
66. Shin Y, Yoon SH, Choe EY, et al. PMA-induced up-regulation of MMP-9 is regulated by a PKCalpha-NF-kappaB cascade in human lung epithelial cells. Exp Mol Med. 2007;39:97-105. (Pubitemid 46356010)
67. Matsumoto G, Namekawa J, Muta M, et al. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005;11:1287-93. (Pubitemid 40175782)
68. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;1:19-26. (Pubitemid 351694451)
69. Horst D, Budczies J, Brabietz T, et al. Invasion Associated Up-Regulation of Nuclear Factor kB Target Genes in Colorectal Cancer. Cancer. 2009;4946-4958.
70. Arnold C, Blum H. Colon cancer: molecular pathogenesis and clinical relevance. Dtsch Med Wochneschr. 2005;130:8009-811.
71. Goa J, Pfeifer D, He LJ, et al. Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations. Scand J Gastroenterol. 2007;42:345-50.